← Browse by Condition
Medical Condition
idh mutation
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT03991832 Phase 2
Recruiting
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
Enrollment
58 pts
Location
Canada
Sponsor
University Health Network, Tor...
NCT07260175 Phase 2
Recruiting
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
Enrollment
40 pts
Location
Germany
Sponsor
Institut für Klinische Krebsfo...